Peroxisome proliferator-activated receptor γ coactivator 1 coactivators, energy homeostasis, and metabolism by Handschin, C. & Spiegelman, B. M.
Peroxisome Proliferator-Activated Receptor 
Coactivator 1 Coactivators, Energy Homeostasis,
and Metabolism
Christoph Handschin and Bruce M. Spiegelman
Dana-Farber Cancer Institute and Department of Cell Biology, Harvard Medical School, Boston, Massachusetts 02115
Manybiologicalprogramsare regulatedat the transcriptional
level. This is generally achieved by the concerted actions of
several transcription factors. Recent findings have shown
that, in many cases, transcriptional coactivators coordinate
the overall regulation of the biological programs. One of the
best-studied examples of coactivator control of metabolic
pathways is the peroxisome proliferator-activated receptor 
coactivator 1 (PGC-1) family. These proteins are strong acti-
vators of mitochondrial function and are thus dominant reg-
ulators of oxidative metabolism in a variety of tissues. The
PGC-1 coactivators themselves are subject to powerful regu-
lation at the transcriptional and posttranslational levels. Re-
cent studies have elucidated the function of the PGC-1 coac-
tivators in different tissues and have highlighted the
implications of PGC-1 dysregulation in diseases such as dia-
betes, obesity, cardiomyopathy, or neurodegeneration.
(Endocrine Reviews 27: 728–735, 2006)
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I. Discovery, Function, and Structure of the PGC-1s
A. Discovery
REGULATION OF GENE transcription is a highly or-chestrated process that involves multiple steps and a
large number of different protein complexes. Transcription
factors bind to specific DNA sequences in the promoter or
enhancer regions of their target genes upon activation or
after being induced themselves. Concomitantly, or in some
cases subsequently, large protein complexes are recruited
to the transcription factor and facilitate opening of the
chromatin structure and initiation of transcription. DNA
binding sequences for any given transcription factors can
usually be found in the regulatory flanking regions of
target genes. However, additional regulatory mechanisms
ensure high specificity in the transcriptional induction of
genes.
Peroxisome proliferator-activated receptor  (PPAR) was
found to be a master regulator of adipogenesis (1–3). In
addition to being absolutely indispensable for white adipose
tissue (WAT) development, PPAR also plays an important
role in brown adipose tissue (BAT). BAT is characterized by
small, multilocular lipid droplets and a high number of mi-
tochondria. In contrast to WAT, which is mainly used for fat
storage, BAT uses lipids as a fuel for adaptive thermogenesis
during cold exposure (4). It was unclear how PPAR can
induce a specific set of genes in WAT, whereas the same
transcription factor can regulate different target genes and
biological programs in BAT. As examples, the fatty acid
binding protein aP2 (also called FABP4) is strongly induced
by PPAR in WAT, whereas other genes, such as the un-
coupling protein 1 (UCP-1), are the main PPAR targets in
BAT. Thus, Puigserver et al. (5) addressed questions about
the molecular mechanisms that determine the specificity of
the PPAR response in these two different tissues. In a yeast
two-hybrid screen using a BAT cDNA library, candidate
proteins binding to PPAR were isolated and subsequently
tested for BAT vs. WAT expression, as well as cold induc-
ibility in BAT. One of the proteins isolated, the PPAR co-
activator 1 (PGC-1) not only fulfills all of these criteria, but
also elevates certain BAT markers when ectopically ex-
pressed in murine WAT cell lines, human white adipocytes,
or mouse WAT in vivo (5, 6). Thus, PGC-1 confers tran-
scriptional specificity to PPAR by coactivating this nuclear
receptor on the UCP-1 but not on the aP2 promoter.
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B. Function and structure
Analysis of PGC-1 function in BAT and tissue expression
patterns immediately suggested that a core function of
PGC-1 might be stimulation of mitochondrial number and
oxidative metabolism. PGC-1 is strongly expressed in BAT,
heart, skeletal muscle, kidney, and brain, all of which are
highly oxidative tissues (7–9). Accordingly, when ectopically
expressed in fat or muscle cells, PGC-1 strongly promotes
increases in mitochondrial DNA as well as the large set of
nuclear andmitochondrial-encodedmitochondrial genes (7).
Mechanistically, PGC-1 induces mitochondrial genes by
increasing the levels of the nuclear respiratory factor 1 and
2 [NRF-1 andNRF-2, alternatively calledGA-binding protein
(GABP), respectively] and the estrogen-related receptor 
(ERR) (7, 10, 11). When coactivated by PGC-1, GABP and
ERR promote their own, as well as each others’ expression,
and subsequently elevate the levels of NRF-1 (10). Subse-
quently, PGC-1 coactivates NRF-1 and GABP binding to
regulatory regions of the mitochondrial transcription factor
A promoter (7). Thus, PGC-1 not only initiates elevation of
mitochondrial biogenesis and oxidativemetabolism, but also
participates in the regulation of the downstream steps of this
biological program.
This core function of PGC-1 is conserved in the two other
members of the PGC-1 family, PGC-1 and the PGC-1-
related coactivator (PRC) (12–14). PGC-1 and PGC-1 both
strongly increase total mitochondrial respiration; however,
PGC-1 elevates uncoupled respiration more than PGC-1,
at least when expressed in cultured myotubes (15). Like
PGC-1, PRC coactivates NRF-1 on the promoters of differ-
ent mitochondrial genes (14). Orthologs of the PGC-1 family
members are found in higher vertebrates, including mam-
mals, birds, and fish (16). No clear PGC-1 orthologs have
been found in lower eukaryotes, including nematodes, in-
sects, or yeast. However, recent findings suggest that medi-
ator-15, which integrates transcriptional regulation of fatty
acid metabolism in Caenorhabditis elegans, might be function-
ally equivalent to PGC-1 in terms of regulation of lipid
metabolism (17).
All three members of the PGC-1 family have a related
modular structure. To date, PGC-1 remains the best studied
and thus will be discussed in more detail here. PGC-1 has
a strong activation domain at theN terminus, which interacts
with a histone acetyltransferase (HAT) complex that includes
steroid receptor coactivator 1 and cAMP response element
binding protein (CREB) binding protein/p300 (18). Adjacent
to theN-terminal domain is an inhibitory region that roughly
spans 200 amino acids. Toward the C terminus, PGC-1
binds the thyroid receptor-associated protein (TRAP)/vita-
min D receptor-interacting protein (DRIP)/Mediator com-
plex that facilitates direct interaction with the transcription
initiation machinery (19). Thus, simultaneous recruitment of
HATproteins and the TRAP/DRIP/Mediator complex prob-
ably explains the exceptionally powerful transcriptional co-
activation capacity of PGC-1. In addition to TRAP/DRIP/
Mediator recruitment, theC terminus of PGC-1 also harbors
RNA recognition and splicing domains (20). Thus, PGC-1
can be described as a protein docking platform that, when
bound to a transcription factor, recruits histone modifying
enzymes, bridges the transcription factor to the basal tran-
scriptional initiation complex, and takes part in processing of
the target gene mRNA. Importantly, the recruitment of the
HAT complex appears to be stimulated by the binding of
PGC-1 to a target transcription factor (18).
II. Specificity of Biological Programs Induced by the
PGC-1s in Different Tissues
A. Tissue-specific functions
PGC-1 and PGC-1 are both expressed in tissues with a
high oxidative capacity, including brown fat, heart, kidney,
skeletal muscle, and brain (5, 12). Whereas PGC-1 and
PGC-1 are more restricted in their tissue expression, PRC is
expressed fairly ubiquitously (14). In addition to their pow-
erful induction of mitochondrial function, PGC-1 family
members activate other tissue-specific functions. For exam-
ple, PGC-1 is a potent regulator of gluconeogenesis and
integrates multiple aspects of the fasting response in the
liver, including heme biosynthesis (21–24). Gluconeogenesis
is directly regulated by PGC-1 via induction of phosphoe-
nol pyruvate carboxykinase and glucose-6-phosphatase and
increased tricarboxylic acid cycle flux, as shown in both gain-
and loss-of-function mouse models (21, 24–26). In skeletal
muscle, PGC-1 promotes glucose uptake and coordinately
induces the expression of skeletal muscle fiber-type I and
IIa-specific genes (27, 28). PGC-1 induces expression of
UCP-1 in BAT and thus regulates adaptive thermogenesis (5,
29). The tissue-specific functions of PGC-1 are less well
studied. In liver, PGC-1 increases lipogenesis and lipopro-
tein transport but has no major effect on gluconeogenesis
(30–32). PGC-1 promotes hepatic lipoprotein metabolism
but has no impact on lipogenesis (23, 30).
B. Regulation of PGC-1 activity: induction,
posttranslational modifications, and binding partners
The potent induction of mitochondrial function as well as
the diverse tissue-specific effects of the PGC-1 family mem-
bers require a very tight regulation of both expression and
activity (16, 33–36). PGC-1 levels are elevated by a number
of external stimuli (Fig. 1): cold in BAT, exercise and de-
creased ATP levels in skeletal muscle, and fasting in liver. A
number of different signaling pathways are involved in
PGC-1 regulation. In particular, cAMP signaling is a key
activator of PGC-1 transcription inmany tissues, promoting
the binding of CREB or the activating transcription factor-2
to a conserved DNA response element in the PGC-1 pro-
moter. CREB is activated upon glucagon signaling in the liver
(22), whereas calcium signaling cascades converge on CREB
in skeletal muscle (37). Activating transcription factor-2 is
recruited to the PGC-1promoter after-adrenergic receptor
activation in BAT (38). Interestingly, nitric oxide increases
PGC-1 levels and mitochondrial biogenesis via cGMP-
dependent pathways (39). In addition, several tissue-specific
transcription factors have been implicated in the transcrip-
tional regulation of PGC-1. In skeletal muscle, myocyte
enhancer factor 2 (MEF2) proteins bind to the PGC-1 pro-
moter (37, 40). Importantly, PGC-1 protein can bind to
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MEF2 on its own promoter and thus regulate its own tran-
scription in a positive autoregulatory loop (37). PGC-1 stim-
ulates its own transcription by coactivating PPAR binding
to the PGC-1 promoter in WAT (41). It therefore seems
likely that at least some transcription factors that are binding
partners for PGC-1 in the regulation of specific gene ex-
pression programs are also upstream of PGC-1 induction.
Another example is Foxo1, which is coactivated by PGC-1
in the regulation of gluconeogenic and heme biosynthetic
genes (24, 42) and binds to insulin responsive sequences in
the PGC-1 promoter (43). Finally, ERR has been found to
bind to response elements in the PGC-1 promoter (44), and
ERR is coactivated by PGC-1 in the induction of PGC-1
target genes (45). These biological loops might provide an
additional degree of specificity in regulating specific biolog-
ical pathways. Thus, many of the tissue-specific effects of the
PGC-1 familymembers can be explained by the coexpression
of a PGC-1 and the respective tissue-restricted transcription
factors, such as regulation of gluconeogenesis and lipopro-
teinmetabolism by PGC-1 and hepatocyte nuclear factor 4
(HNF4) in the liver (23, 46).
Secondly, the relative activity of the PGC-1s is modulated
by posttranslational modifications. The half-life of PGC-1
protein is relatively short (2.28 h) (47). Thus, upon cessation
of stimulatory pathways on PGC-1 transcription, the
PGC-1 protein is rapidly degraded and the potentially
wasteful (and possibly pathogenic) induction of many
PGC-1 downstream target genes will return to basal levels.
However, subsequent to phosphorylation by p38MAPK, the
half-life of PGC-1 protein is tripled, and thus higher
PGC-1 protein levels are observed (47). Moreover, these
phosphorylation events lead to release of factors inhibitory
toward PGC-1 (48), such as p160 myb binding protein (49).
In addition to phosphorylation, PGC-1 protein is also acety-
lated (50) and methylated (51). Deacetylation of PGC-1
through sirtuin 1 increases PGC-1 activity on gluconeogenic
gene transcription in the liver (50). Interestingly, acetylation
of PGC-1 by GCN5 not only decreases PGC-1 activity but
also relocates PGC-1 within the nucleus (50, 52). Protein
arginine methyltransferase 1 methylates PGC-1 in the C-
terminal region and enhances its transcriptional activity (51).
Finally, and probably most importantly, PGC-1 activity
is controlled by the repertoire of transcription factor binding
partners in particular tissues.Asmentionedpreviously,HAT
and TRAP/DRIP/Mediator complexes are the major factors
by which PGC-1 stimulates transcription. Upon binding to
PPAR, PGC-1 changes conformation that then allows
docking of the HAT complex (18). On the other hand, p160
myb binding protein binding to nonphosphorylated PGC-1
represses transcriptional activity, possibly by recruiting
histone deacetylase complexes and/or promoting PGC-1
protein degradation (49). In the context of the carnitine
palmitoyltransferase-1 (CPT-1) promoter, the upstream
stimulatory factor 2 has been found to bind to theN terminus
of PGC-1 and repress coactivation of MEF2A by PGC-1
(53). The orphan nuclear receptor small heterodimer partner
competes with PGC-1 for binding to the glucocorticoid re-
ceptor on the phosphoenol pyruvate carboxykinase pro-
moter (54). Transcriptional activation of HNF4 by PGC-1
is reduced by the nuclear receptor pregnaneX receptor on the
cytochrome P450 7A1 promoter (55). Upon ligand activation,
pregnane X receptor binds to PGC-1 and thus results in
dissociation of PGC-1 from HNF4 (55).
The relative activity of the PGC-1 coactivators in different
tissues is thus regulated at multiple different levels. How-
ever, regulation and determination of specificity could ad-
ditionally be mediated by posttranslational modifications of
PGC-1 protein that “educate” this transcriptional coactiva-
tor. Similar to the “phospho-code” proposed for the steroid
receptor coactivators (56), modification of PGC-1 could con-
fer a preference to the PGC-1 proteins to bind to specific
transcription factors or recruit particular binding partners
that then result in the regulation of selective gene expression
programs (Fig. 2). For example, PGC-1 is induced in skeletal
muscle by AMP-dependent protein kinase (AMPK) when
ATP levels are low (57). However, it would be extremely
wasteful to elevate the entire set of PGC-1-controlled genes
in skeletal muscle, including skeletal muscle fiber-type-spe-
cificmyofibrillar genes. Indeed,AMPKonly elevates a subset
of genes that are regulated by PGC-1, such as the glucose
transporter GLUT4, cytochrome c, and -aminolevulinate
synthase (ALAS) (58, 59). No fiber-type switching after
AMPK activation has been reported; furthermore, even some
metabolic genes like palmitoyltransferase-1 that are acti-
vated by PGC-1 remain unchanged upon AMPK signaling
(58). Thus, posttranslational modifications of PGC-1 after
AMPK activation most likely direct downstream gene in-
duction toward very specific pathways, possibly due to pref-
erential transcription factor binding (Fig. 2B). In the liver,
deacetylation of PGC-1 by sirtuin 1 boosts PGC-1 activity
on gluconeogenic, but not on oxidative phosphorylation
(OXPHOS) gene induction (50). In addition to posttransla-
tionalmodifications, different splice variants for PGC-1 and
PGC-1 have been observed (60, 61). These might arise from
FIG. 1. Regulation of PGC-1 transcription. PGC-1 levels are ele-
vated by various stimuli in different tissues. Many of the signaling
pathways activated in these contexts converge on the functional DNA
binding elements that have been identified so far in the PGC-1
promoter region.Moreover, PGC-1 regulates its own transcription in
a positive autoregulatory loop. Interestingly, many of the transcrip-
tion factors involved in PGC-1 regulation are also downstream bind-
ing partners for PGC-1, such as Foxo1, PPAR, or MEF2. NO, Nitric
oxide; IRS, insulin responsive sequence (binding site for Foxo1);
PPRE, PPAR response element; CRE, cAMP responsive element.
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differential internal splicing as well as alternative promoter
usage. Intriguingly, PGC-1 is involved in transcription ini-
tiation, elongation, and processing (20) and could thus reg-
ulate its own mRNA splicing. For example, a PGC-1 splice
variant lacking the interactiondomainwith nuclear receptors
would specifically bind to and activate transcription factors
of the nonnuclear receptor families (Fig. 2C).APGC-1 splice
variant lacking one of its interaction domains has been de-
scribed, and this PGC-1 allele exhibits reduced coactivation
of estrogen receptor comparedwith full-length PGC-1 (13,
62).
Alternatively, recruitment of specific coactivators by tran-
scription factors can be regulated by particular DNA binding
elements, as has been elegantly shown for nuclear factor b
(63). PGC-1 preferentially induces UCP-1 but not aP2, even
though both are PPAR target genes (5). In the liver, only a
subset of HNF4 target genes are induced by PGC-1, al-
thoughPGC-1 is a very powerful coactivator ofHNF4 (23).
Finally, despite being potent transcriptional coactivators of
the liver X receptor, PGC-1 and PGC-1 are only recruited
to the cytochrome P450 7A1 and theATP-binding cassette A1
promoters but not to liver X receptor  binding to the sterol
regulatory element-binding protein 1 (SREBP1) promoter
(30). In the same context, PGC-1 coactivates SREBP1c in the
transcriptional induction of fatty acid synthase but is not
recruited to SREBP1c at the low-density lipoprotein receptor
promoter (30). In a recent report, hepatic lipin 1 was found
to selectively amplify the PGC-1-PPAR axis but not other
FIG. 2. Specificity of PGC-1-regulated bi-
ological programs. A, Ectopic expression of
PGC-1 results in the induction of target
genes that represent different biological
programs. B, In certain contexts, PGC-1
is posttranslationally modified, which
might affect its relative binding affinity to
transcription factor Z as opposed to X and
Y. This will result in preferential induction
of gene program C. C, Alternative pro-
moter usage and splicing of the PGC-1
transcript results in different PGC-1 pro-
teins. A PGC-1 splice variant that lacks
binding domains for transcription factors
Y and Z will only bind to factor X and thus
increase transcription of gene program A.
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PGC-1 target genes in the liver (64). Thus, additional com-
ponents of the PGC-1 complexes might control PGC-1
specificity.
Elucidating the molecular mechanisms underlying the
specification of PGC-1 in different tissues and contexts will
be one of the biggest challenges and breakthroughs in dis-
secting the roles for these coactivators in the future. Knowl-
edge of these mechanisms would allow researchers to spe-
cifically target certain functions of PGC-1 that might be
beneficial in a disease state while avoiding detrimental
properties.
III. PGC-1s in Health and Disease
Aberrant mitochondrial function has been associated with
a vast number of human pathologies (65, 66). It is thus not
surprising that dysregulated PGC-1 levels have been asso-
ciated with many disease states in different tissues.
A. Brain
Several neurodegenerative diseases have been linkedwith
impaired mitochondrial function and decreased expression
of genes involved in mitochondrial OXPHOS, most promi-
nently Parkinson’s disease, Alzheimer’s disease, and Hun-
tington’s disease (67). PGC-1 deficiency in knockout animal
models result in behavioral changes and neurodegeneration
(29, 68). One of the two published PGC-1 knockout mouse
lines exhibits signs of increased anxiety (68), whereas the
other mouse line is hyperactive (29). This hyperactivity and
other behavioral peculiarities such as stimulus-induced my-
oclonus, exaggerated startling response, dystonic posturing,
and frequent limb clasping are reminiscent of mouse models
for Huntington’s disease. Indeed, PGC-1 knockout mice
have a striking spongiform lesion in the striatum, the brain
region primarily affected in human Huntington’s disease
and which is important in the control of movement (29).
However, sporadic lesions were also observed in the cortex
of PGC-1 knockoutmice, including the substantia nigra and
hippocampus, two regions that are severely affected in Par-
kinson’s and Alzheimer’s, respectively (29).
B. Peripheral metabolic tissues
In recent years, strong evidence for mitochondrial dys-
regulation in type 2 diabetes has been found (69). In muscle
biopsies of type 2 diabetic patients, OXPHOS gene expres-
sion is reduced (70, 71). These dysregulated OXPHOS genes
are transcriptional targets for PGC-1 and PGC-1 and, ac-
cordingly, the relative levels of PGC-1 and PGC-1 are lower
in skeletal muscle of type 2 diabetic patients (70, 71). Impor-
tantly, OXPHOS and PGC-1 dysregulation is also found in
first-degree familymembers of type 2 diabetic patients (70) and
individuals with impaired glucose tolerance (71), suggesting
that aberrant expression of PGC-1 andOXPHOS is found early
in thedevelopment of thedisease. In amonozygotic twin study,
PGC-1 expression has been found to correlate with insulin-
stimulated glucose uptake and oxidation (72). In contrast,
PGC-1 expressionwas found to be related to fat oxidation and
nonoxidative glucose metabolism (72). Expression of both
PGC-1 and PGC-1 decreases in age; this correlation might
provide an explanation by which age influences the suscepti-
bility to type2diabetes (72). Finally, aGly482Serpolymorphism
in PGC-1 has been associated with type 2 diabetes in several
different populations (35). However, causality of PGC-1 dys-
regulation in the pathogenesis of type 2 diabetes has not been
shownyet.Moreover, at least one other study failed to replicate
the PGC-1 dysregulation in skeletal muscle of type 2 diabetic
patients (73). Thus, the role for PGC-1 and PGC-1 dysregu-
lation on type 2 diabetes in skeletal muscle warrants further
studies.
PGC-1 expression is reduced in WAT of morbidly obese
subjects (74) and in sc fat of insulin resistant individuals (75).
Rosiglitazone treatment of obese mice boosts PGC-1 tran-
scription in WAT concomitant with increased mitochondrial
function and, more importantly, insulin sensitivity (76). In-
creasing PGC-1 levels in skeletal muscle and WAT would
therefore be potentially beneficial in the treatment of type 2
diabetes. In contrast, PGC-1 is elevated in the liver and
pancreas of rodent models of type 1 and type 2 diabetes (21,
77). In these tissues, increased PGC-1 levels can account for
elevated gluconeogenesis and decreased insulin secretion in
diabetes, respectively (21, 77). Moreover, PGC-1 promotes
hepatic insulin resistance (26). To achieve a net beneficial
effect ofmodulating PGC-1 levels, tissue-specific effects have
to be taken into consideration. Interestingly, PGC-1 regu-
lates OXPHOS genes in skeletal muscle by inducing and
binding to ERR and GABP (10, 11). Disruption of the
PGC-1 and ERR interaction in skeletal muscle provokes a
type 2 diabetes-like phenotype without affecting gluconeo-
genesis in liver cells (10). Enhancing the coactivation of ERR
by PGC-1 might therefore be a valid approach to boost
OXPHOS gene expression in skeletal muscle without detri-
mental effects on gluconeogenesis in the liver (78).
Regulation of PGC-1 in fasting and feeding has addi-
tional implications in patients suffering from hepatic por-
phyrias with inherited defects in heme biosynthesis. In sus-
ceptible individuals, fasting can trigger an acute, potentially
life-threatening, porphyric attack (79). PGC-1 induces the
first and rate-limiting step of heme biosynthesis, ALAS, by
binding to NRF-1 and Foxo1 in the fasted liver (24). Indeed,
liver-specific PGC-1 knockout animals have blunted induc-
tion of ALAS (24). Moreover, ectopic expression of PGC-1
can trigger an acute porphyric attack in mouse models with
chemically induced porphyria, whereas liver-specific
PGC-1 knockout animals are protected from fasting-in-
duced acute attacks in chemical porphyria (24). These find-
ings have implications both on the prevention as well as the
treatment of acute porphyric attacks (80).
C. Heart
PGC-1 expression is reduced in a number of animalmod-
els of heart disease, often accompanied by a switch of sub-
strate use from fatty acids to glucose (81, 82). Accordingly,
hearts from PGC-1 knockout animals appear normal at
baseline but are unable to increase their workload when
stimulated by adrenergic agonists, suggesting an important
role for PGC-1 in cardiac reserve (83). Moreover, PGC-1
knockout mice exhibit lower treadmill running times and
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diminished cardiac function after exercise (68). Consistent
with the reduced expression of PGC-1 in animal models of
heart failure, transverse aortic constriction in PGC-1 knock-
out animals accelerates cardiac dysfunction and clinical signs
of heart failure (84), suggesting that decreased PGC-1 ex-
pression in heart disease is maladaptive. On the other hand,
superphysiological expression of PGC-1 in the heart leads
to mitochondrial proliferation, myofibrillar displacement,
and eventually, cardiac dilation and failure in mice (85, 86).
Thus, therapeutic regulation of PGC-1 in heart failure
should aim at achieving moderate induction of PGC-1
within a therapeutically beneficial window.
The first description of PGC-1 in 1998 and the numerous
papers after that established the PGC-1 family of transcrip-
tional coactivators as master regulators of mitochondrial
function and oxidative metabolism. Thus, these proteins
have great potential in the prevention and treatment of dis-
eases associatedwith impairedmitochondrial biology.More-
over, the high transcriptional inducibility of PGC-1 sug-
gests that regulation of this gene should be amenable to
pharmacological interventions. However, it is clear that sev-
eral challenges in understanding the role of dysregulation of
the PGC-1s in human pathophysiology are still ahead. First,
although we have a relatively good understanding of many
functions of PGC-1 in different tissues, our knowledge
about PGC-1 and especially PRC is still rudimentary. A
mouse model that ectopically expresses PGC-1 in a number
of tissues has increased oxidative capacity in muscle, in-
creased energy expenditure, lower insulin levels, and resis-
tance to obesity (62). However, the specific functions of
PGC-1 in different tissues remain to be elucidated. Sec-
ondly, as mentioned above, we will have to understand the
mechanisms controlling the specificity of the PGC-1-medi-
ated coactivation in different contexts. Thirdly, because of
the complex phenotype of the whole-body knockout of PGC-
1, the PGC-1s will have to be deleted in a tissue- and per-
haps developmental stage-specific manner to dissect their
functions in peripheral tissues. These studies should be com-
bined with tissue-specific gain-of-function animal models to
test potential therapeutic effects of elevated PGC-1 expres-
sion, with the caveat that superphysiological expression can
itself lead to pathogenesis, as observed in the heart. Once we
have a firmer grip on the actions and regulations of the
PGC-1s in different tissues and contexts, this knowledge is
likely to result in novel approaches in the therapy of diseases
that have been associated with mitochondrial dysfunction.
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